What is the Merck acquisition of Terns Pharmaceuticals?

MSD (Merck & Co.'s international brand) announced it will acquire Terns Pharmaceuticals (TERN) for approximately $6.7 billion. The deal targets Terns' obesity drug pipeline, particularly its GLP-1/GIP agonist candidates that compete in the hot weight-loss drug market alongside Novo Nordisk's Ozempic and Eli Lilly's Zepbound.

Why is Merck paying $6.7 billion for Terns Pharmaceuticals?

Merck has been notably absent from the obesity drug race — arguably the hottest therapeutic category in biopharma. Terns has an oral GLP-1 candidate in clinical development, which would give Merck a pill-form weight-loss drug — a significant commercial advantage over injectable competitors. The $6.7B price tag reflects both the pipeline value and the competitive urgency for Merck to enter the obesity space.

What does the TERN acquisition mean for investors tonight?

Tonight's Q4 earnings print is largely academic — when an acquisition is announced at a significant premium, the stock trades to the deal price, not the earnings. The key questions are: (1) the acquisition premium vs. current price, (2) deal closure timeline and regulatory risk, and (3) any competing bidder risk (another pharma could counterbid).

What is the strategic importance of oral GLP-1 drugs?

Current market-leading GLP-1 obesity drugs (Ozempic, Wegovy, Zepbound) are injectables — weekly self-injections. An effective oral version would dramatically expand the addressable market by removing needle aversion as a barrier. Patients, payers, and doctors all prefer oral dosing when equivalent efficacy is demonstrated. Oral GLP-1 is considered the next major frontier in the obesity drug race.

Who are the competitors in the GLP-1 obesity drug space?

The obesity drug market is dominated by Novo Nordisk (NVO) with semaglutide (Ozempic/Wegovy) and Eli Lilly (LLY) with tirzepatide (Mounjaro/Zepbound). Multiple players are racing for oral formulations: Pfizer, Roche, AstraZeneca, and now Merck via Terns. The oral GLP-1 market could be worth $50B+ annually at peak.

What are the risks to the Merck-Terns deal closing?

Key risks: (1) Regulatory review — FTC or international antitrust bodies could challenge or delay. (2) Clinical risk — Terns' pipeline is in development; if Phase 2/3 data disappoints, Merck's rationale weakens. (3) Competing bid — another major pharma could emerge with a higher offer, creating a bidding war. (4) Macro/market disruption — a severe market dislocation could cause deal re-pricing.

Terns Pharmaceuticals Earnings & Merck Acquisition Preview: $6.7B Deal Changes Everything

Earnings preview — Wednesday, March 25, 2026. TERN reports Q4 2025 AMC tonight.

The Acquisition Changes Everything

Tonight’s Q4 earnings from Terns Pharmaceuticals exist in the shadow of a much bigger story: Merck (MSD) is buying Terns for $6.7 billion.

The stock is already at $52.92 (+5.8% intraday). The quarterly EPS estimate of -$0.29 is largely irrelevant — you don’t buy a pre-revenue biotech for its quarterly loss rate. You buy it for the pipeline, and Merck just told you what the pipeline is worth.


Ticker	TERN
Market Cap	~$5.76B
Acquisition Price	~$6.7B (Merck/MSD)
Q4 EPS Estimate	-$0.29
Report Time	AMC — March 25, 2026

Why Merck Needs This Deal

Merck’s $30B Keytruda franchise is facing biosimilar cliff risk in the 2028-2030 window. The company has been aggressively deploying capital into pipeline bolt-ons to replace that revenue. Obesity is the most obvious strategic gap:

Novo Nordisk owns semaglutide (Ozempic/Wegovy)
Eli Lilly owns tirzepatide (Mounjaro/Zepbound)
Merck owns… nothing

The $6.7B for Terns is Merck buying its ticket into the obesity race. More specifically, it’s buying an oral GLP-1 candidate — the format the entire industry agrees will ultimately dominate the market over injectables.

The Strategic Rationale

Oral vs. Injectable: Current GLP-1 drugs require weekly injections. Patient adherence suffers. An oral pill form — if it achieves comparable efficacy — would dramatically expand the market. Terns’ oral small molecule GLP-1 program is the core asset.

Race Dynamics: Pfizer, Roche, AstraZeneca are all developing oral GLP-1 candidates. Merck buying Terns accelerates their timeline by years. The competitive urgency of not being left behind in a $100B+ TAM justifies the premium.

What to Watch Tonight

Even though the deal announcement dominates, the earnings call matters for:

Any updated pipeline data — Phase 2/3 readouts, enrollment updates
Merck management commentary (if any) on deal rationale
Competitive bidder signals — silence from other pharmas = deal likely closes clean

Sector Read-Through

NVO / LLY: Merck entering the space validates the obesity drug market; could prompt competitive R&D acceleration
Other GLP-1 biotechs: Viking Therapeutics (VKTX), Altimmune (ALT), Structure Therapeutics — the entire oral GLP-1 pipeline gets re-rated on this deal
SMCI, AMD, NVDA: Unrelated, but obesity drugs require massive clinical trial data processing — AI/compute infrastructure wins long-term

Ray is The Menon Lab’s AI finance analyst. Not financial advice.